| Q57780536 | 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients |
| Q39176719 | 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer. |
| Q38098442 | 11C-choline PET/CT and PSA kinetics |
| Q39293042 | 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. |
| Q47273452 | 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making |
| Q27000180 | A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer |
| Q85822182 | Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only |
| Q39472939 | An imaging-based approach predicts clinical outcomes in prostate cancer through a novel support vector machine classification |
| Q61448475 | Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial |
| Q61452678 | Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies |
| Q52983462 | Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer? |
| Q36124719 | Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection |
| Q35849174 | Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse |
| Q53171288 | Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. |
| Q41319390 | Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer |
| Q38109258 | Developments in external beam radiotherapy for prostate cancer |
| Q50721465 | Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. |
| Q34485009 | Evaluation of 11C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study |
| Q90431392 | Extended robotic salvage lymphadenectomy in patients with 'node-only' prostate cancer recurrence: initial experience |
| Q42005117 | Extended salvage pelvic lymph node dissection in patients with recurrent prostate cancer |
| Q50138461 | Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-Based Approach |
| Q58433797 | Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivo |
| Q91106465 | Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study |
| Q38321182 | Imaging biomarkers in prostate cancer: role of PET/CT and MRI. |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q56359100 | Imaging of Prostate Cancer Using C-Choline PET/Computed Tomography |
| Q51058133 | Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. |
| Q50665259 | Is there a role for salvage lymphadenectomy as second line therapy post robotic radical prostatectomy? |
| Q51799851 | MR-based prognostic nomogram for prostate cancer after radical prostatectomy. |
| Q47710564 | Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands |
| Q34748629 | Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options |
| Q26740069 | Oligometastatic prostate cancer: Metastases-directed therapy? |
| Q56383213 | Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row |
| Q39242140 | PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies |
| Q38983526 | PET imaging for lymph node dissection in prostate cancer. |
| Q87856080 | PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy? |
| Q38996907 | Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography |
| Q52991043 | Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. |
| Q49096071 | Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer |
| Q55250174 | Prostate Cancer - Local Treatment after Radiorecurrence: Surgery - Back to the future? |
| Q87354549 | Prostate cancer: The role of local therapy for metastatic prostate cancer |
| Q51008062 | Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. |
| Q92057233 | Salvage lymph node dissection in hormone-naïve men: How effective is surgery? |
| Q42785526 | Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome. |
| Q42716680 | Study of inter- and intra-observer reproducibility in the interpretation of [(18)F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment. |
| Q27013035 | Surgical resection of urological tumor metastases following medical treatment |
| Q35604502 | Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up |
| Q51073020 | The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. |
| Q49919217 | The use of PET/CT in prostate cancer |
| Q57109624 | The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis |
| Q52983467 | Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. |
| Q34611812 | Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer |
| Q37244969 | Translational Molecular Imaging of Prostate Cancer |
| Q50906241 | Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. |
| Q40468376 | Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. |
| Q38802235 | Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. |
| Q53094162 | Writing PET into existence. |
| Q36489655 | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
| Q53060499 | [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. |
| Q57780535 | [11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy |
| Q91896916 | [Oligometastatic prostate cancer management] |
| Q53549289 | [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]. |
| Q53173958 | [Resection of metastases from prostate cancer]. |
| Q53804889 | [Salvage lymphadenectomy in patients with prostate cancer recurrence: A review]. |
| Q52889384 | [When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?] |